NDA 020428 · Almirall
Azelex
Azelaic Acid · Topical
NovelLast checked: Nov 19, 2026Latest source record: Feb 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Sep 13, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
9 Phase 3, 1 recruiting
FAERS reports
977
510 serious, 86 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2026.
INDICATIONS AND USAGE AZELEX ® cream is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 1995 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- AZELEX · AZELAIC ACID 20% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Azelaic Acid" as an intervention, any sponsor and status, largest first.
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
- To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial RosaceaPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT03689010 · 1,116 participants · Start Dec 12, 2017 · Primary completion Aug 9, 2018
Drug: Azelaic acid foam 15%; Finacea® (Azelaic acid Foam) 15% and 1 more · For: Rosacea
Sites: Charlotte, North Carolina
- A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial RosaceaPivotal-lookingCompleted
Actavis Inc.Industry
NCT02120924 · 1,009 participants · Start Jul 2013 · Primary completion Sep 2014
Drug: Azelaic acid; Vehicle and 1 more · For: Rosacea
Sites: Fremont, California; Santa Monica, California; Brandon, Florida · 30 sites in all
- To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical GelPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT03094403 · 1,000 participants · Start Jul 1, 2016 · Primary completion Mar 31, 2017
Drug: Azelaic Acid 15% topical gel; Finacea® (azelaic acid) Gel, 15% and 1 more · For: Rosacea
- Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular RosaceaPivotal-lookingCompleted
LEO PharmaIndustry
NCT01555463 · 961 participants · Start Sep 2012 · Primary completion Jan 2014
Drug: Azelaic acid foam, 15% (BAY39-6251); Vehicle foam · For: Papulopustular Rosacea
Sites: Birmingham, Alabama; Fremont, California; Los Angeles, California · 49 sites in all
- A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With RosaceaPivotal-lookingCompleted
Actavis Inc.Industry
NCT03287791 · 924 participants · Start Jul 19, 2016 · Primary completion Jun 22, 2017
Drug: Generic Azelaic Acid Foam; Finacea® (Azelaic Acid) Foam and 1 more · For: Rosacea
Sites: Encino, California; La Mesa, California; Brandon, Florida · 26 sites in all
- Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate AcnePivotal-lookingCompleted
LEO PharmaIndustry
NCT00031096 · 879 participants · Start Jan 2002 · Primary completion Jul 2002
Drug: Azelaic Acid Gel 15% (Finacea, BAY39-6251); Vehicle gel (SH H 655 PBA) · For: Acne Vulgaris
Sites: Mobile, Alabama; Boulder, Colorado; Newnan, Georgia · 16 sites in all
- Phase 3 Papulopustular Rosacea StudyPivotal-lookingCompleted
Galderma R&DIndustry
NCT01494467 · 688 participants · Start Dec 2011 · Primary completion Aug 2013
Drug: CD5024; Azelaic acid 15% Gel · For: Papulopustular Rosacea
Sites: Birmingham, Alabama; Mobile, Alabama; Hot Springs, Arkansas · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective172
- pain142
- off label use125
- vomiting113
- abdominal pain upper111
- rash108
- product use in unapproved indication107
- gastrooesophageal reflux disease104
- migraine104
- paraesthesia103
- memory impairment100
- hypoaesthesia99
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 15 |
| 2011 | 6 |
| 2012 | 18 |
| 2013 | 10 |
| 2014 | 15 |
| 2015 | 27 |
| 2016 | 29 |
| 2017 | 19 |
| 2018 | 30 |
| 2019 | 39 |
| 2020 | 65 |
| 2021 | 80 |
| 2022 | 70 |
| 2023 | 88 |
| 2024 | 139 |
| 2025 | 146 |
| 2026 | 155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azelex (Azelaic Acid)
2024 spending
$1.5M
Beneficiaries
1,175
2,095 claims
Per beneficiary
$1,247
$16.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,068,798 |
| 2021 | $1,378,645 |
| 2022 | $1,395,398 |
| 2023 | $1,511,623 |
| 2024 | $1,465,383 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Cosmeceuticals in photoaging: A review.
Chan LKW, Lee KWA, Lee CH, et al. · Skin Res Technol 2024 · Systematic Review
- Treatment of keratosis pilaris and its variants: a systematic review.
Maghfour J, Ly S, Haidari W, et al. · J Dermatolog Treat 2022 · Systematic Review
- Perioral dermatitis: Diagnosis, proposed etiologies, and management.
Searle T, Ali FR, Al-Niaimi F · J Cosmet Dermatol 2021 · Systematic Review
- Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.
Liu H, Yu H, Xia J, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials.
Liu Y, Wu S, Wu H, et al. · Front Med (Lausanne) 2021 · Systematic Review
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.